Its receptor antagonists tocilizumab and sarilumab have shown potential benefit in selected patients with severe COVID-19, particularly in hyperinflammatory subgroups characterized by markedly elevated C-reactive protein and IL-6 concentrations (121, 122). The gene discussed is IL6; the disease is COVID-19.